Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.
- DOI
- 10.1016/j.kint.2026.08.021
- Published
- 2026 Sep 23
- Container
- Kidney international
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.kint.2026.08.021,
title = {Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.},
author = {Weir MR and Bhaduri S and Lee K and Galvez O and Kooienga L and Kopjar B and Novin M and Rodman D and Explore-CKD Trial Group},
year = {2026},
journal = {Kidney international},
doi = {10.1016/j.kint.2026.08.021},
url = {https://doi.org/10.1016/j.kint.2026.08.021}
}RIS
TY - JOUR TI - Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. AU - Weir MR AU - Bhaduri S AU - Lee K AU - Galvez O AU - Kooienga L AU - Kopjar B AU - Novin M AU - Rodman D AU - Explore-CKD Trial Group PY - 2026 JO - Kidney international DO - 10.1016/j.kint.2026.08.021 UR - https://doi.org/10.1016/j.kint.2026.08.021 ER -
APA
MR, W., S, B., K, L., O, G., L, K., B, K., M, N., D, R., & Group, E. T. (2026). Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.. Kidney international. https://doi.org/10.1016/j.kint.2026.08.021
Source records
- pubmed · retrieved 2026-09-25T00:19:26.684Z